ChromaDex Corporation (CDXC) financial statements (2022 and earlier)

Company profile

Business Address 10900 WILSHIRE BLVD
LOS ANGELES, CA 90024
State of Incorp. DE
Fiscal Year End December 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments28,21916,69718,81222,61645,3891,6425,550
Cash and cash equivalents28,21916,69718,81222,61645,3891,6425,550
Receivables5,226(1,100)2,1755,0595,3385,8522,451
Inventory, net of allowances, customer advances and progress billings13,60111,68311,5358,2495,7967,9138,174
Inventory13,60111,68311,5358,2495,7967,9138,174
Other undisclosed current assets1,8594,939996610655330374
Total current assets:48,90532,21933,51836,53457,17815,73716,548
Noncurrent Assets
Operating lease, right-of-use asset4,3521,226891
Property, plant and equipment 3,2063,7653,5852,8723,1111,789
Long-term investments and receivables     20 
Long-term investments     20 
Intangible assets, net (including goodwill)8571,0821,3111,5471,651486354
Intangible assets, net (excluding goodwill)8571,0821,3111,5471,651486354
Regulated entity, other noncurrent assets59   115  
Deposits noncurrent assets   24327239759
Other noncurrent assets723625762323   
Other undisclosed noncurrent assets2,944   635  
Total noncurrent assets:8,9356,1396,7295,6985,5454,0152,202
TOTAL ASSETS:57,84038,35840,24742,23262,72419,75218,749
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16,90415,57814,04113,8617,4648,1487,595
Accounts payable10,4239,4459,6269,5483,7185,9786,224
Accrued liabilities6,4816,1334,4154,3133,6452,1701,303
Employee-related liabilities    100  
Interest and dividends payable      68
Deferred revenue161  
Debt20620853137310344445
Due to related parties    100  
Deferred revenue and credits1311147640
Other undisclosed current liabilities5282781693111003001,508
Total current liabilities:17,61316,47615,06314,4408,0888,8699,587
Noncurrent Liabilities
Long-term debt and lease obligation4,1541,0178661373103443,790
Long-term debt, excluding current maturities      3,345
Finance lease, liability 2018
Capital lease obligations137310344445
Operating lease, liability4,154997848
Liabilities, other than long-term debt4,3464,4413,873264366288(133)
Deferred revenue and credits264366288(133)
Deferred revenue4,3464,4413,873
Other undisclosed noncurrent liabilities   213126277231
Total noncurrent liabilities:8,5005,4584,7396148029093,888
Total liabilities:26,11321,93419,80215,0548,8909,77813,475
Stockholders' equity
Stockholders' equity attributable to parent, including:31,72716,42420,44527,17853,8349,9745,275
Common stock686260555538108
Additional paid in capital200,614158,190142,285116,876110,38055,16047,462
Accumulated deficit(168,953)(141,825)(121,900)(89,753)(56,601)(45,224)(42,295)
Other undisclosed stockholders' equity attributable to parent(2)(3)     
Total stockholders' equity:31,72716,42420,44527,17853,8349,9745,275
TOTAL LIABILITIES AND EQUITY:57,84038,35840,24742,23262,72419,75218,749

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues67,44959,25746,29131,55721,20126,81122,014
Revenue, net3,30021,20126,81122,014
Revenue from related parties9,3009,3007,300 
Cost of revenue(25,959)(23,983)(20,522)(15,502)(10,724)(14,890)(13,533)
Gross profit:41,49035,27425,76916,05510,47711,9218,481
Operating expenses(68,563)(55,128)(57,069)(49,227)(26,854)(14,167)(10,635)
Operating loss:(27,073)(19,854)(31,300)(33,172)(16,377)(2,245)(2,154)
Nonoperating expense (71)(847)(144)(153)(683)(613)
Investment income, nonoperating    5,46723
Interest and debt expense(55)(71)(847)(65)(153)(313)(616)
Loss from continuing operations before equity method investments, income taxes:(27,128)(19,996)(32,994)(33,381)(16,683)(3,241)(3,383)
Other undisclosed income from continuing operations before income taxes    153313616
Loss from continuing operations before income taxes:(27,128)(19,996)(32,994)(33,381)(16,530)(2,928)(2,767)
Income tax expense      (5)
Loss from continuing operations:(27,128)(19,996)(32,994)(33,381)(16,530)(2,928)(2,771)
Income from discontinued operations    5,152  
Net loss:(27,128)(19,996)(32,994)(33,381)(11,378)(2,928)(2,771)
Other undisclosed net income attributable to parent 7184765   
Net loss available to common stockholders, basic:(27,128)(19,925)(32,147)(33,316)(11,378)(2,928)(2,771)
Dilutive securities, effect on basic earnings per share 11,914     
Net loss available to common stockholders, diluted:(27,128)(8,011)(32,147)(33,316)(11,378)(2,928)(2,771)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(27,128)(19,996)(32,994)(33,381)(11,378)(2,928)(2,771)
Comprehensive loss, net of tax, attributable to parent:(27,128)(19,996)(32,994)(33,381)(11,378)(2,928)(2,771)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: